A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of ...
International equities added another 5% in the fourth quarter, finishing up more than 30% for the year, the largest gain ...
Exhausted no matter how much you sleep? You could be one of the 3.3 million Americans struggling with chronic fatigue. The ...
Ketamine, a decades-old anesthetic and fast-acting treatment for severe depression, may also offer some people rapid relief from chronic fatigue, according to a small proof-of-concept study led by ...
Ketamine may ease chronic fatigue in cancer survivors and patients with fibromyalgia, lupus, per Rutgers study. Single infusion showed 39% fatigue reduction.
The U.S. Food and Drug Administration (FDA) recently approved the use of Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with Velcade (bortezomib), Revlimid (l ...
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) and Sapu Bioscience today announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-β ...
New long-term data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease.1 These data ...
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
(PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results